greeksoup/ stocks
Stocks / United States / MDT / Q3 FY2025

Medtronic plc Q3 FY2025 results: revenue $8.3 billion, up 2.5% on the year

Medtronic plc (MDT) reported revenue of $8.3 billion for Q3 FY2025, the quarter ended 24 January 2025, up 2.5% on the same quarter a year earlier. Net income was $1.3 billion, down 2.1% on the year, and diluted earnings per share $1.01. The figures are the company's own, from the 10-Q it filed with the SEC on 25 February 2025.

Revenue$8.3 billionup 2.5%
Net income$1.3 billiondown 2.1%
Diluted EPS$1.01
QuarterQ3 FY2025ended 24 January 2025

The quarter, against the one before and a year earlier

LineQ3 FY2025Q2 FY2025Q3 FY2024Change on the year
Revenue8,2928,4038,089+2.5%
Cost of revenue2,7792,9462,782-0.1%
Gross profit5,5135,4575,307+3.9%
Gross margin66.5%64.9%65.6%
Research and development675697695-2.9%
Selling, general and administrative2,7172,7572,673+1.6%
Operating income1,6461,5951,483+11.0%
Operating margin19.9%19.0%18.3%
Interest expense179209188-4.8%
Pre-tax income1,5401,5591,472+4.6%
Income tax237281135+75.6%
Effective tax rate15.4%18.0%9.2%
Net income1,2941,2701,322-2.1%
Net margin15.6%15.1%16.3%
Diluted EPS$1.01$0.99$0.99+2.0%

$ million except per share. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ3 FY2025Q2 FY2025Q3 FY2024Change on the year
Operating cash flow2,5729582,474+4.0%
Capital expenditure476404346+37.6%
Free cash flow2,0965542,128-1.5%
Free cash flow margin25.3%6.6%26.3%
Depreciation and amortisation684675649+5.4%
Share-based compensation98.015985.0+15.3%
Buybacks181288132+37.1%
Dividends paid897897917-2.2%
Dividend per share$0.70$0.70$0.69+1.4%
Diluted shares, weighted1,286m1,287m1,332m-3.4%
Shares outstanding at period end1,283m1,283m1,330m-3.5%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ3 FY2025Q2 FY2025Q3 FY2024Change on the year
Total assets89,97390,04290,836-1.0%
Cash and equivalents1,2401,3941,623-23.6%
Receivables6,1156,2605,968+2.5%
Inventory5,6105,4795,726-2.0%
Goodwill40,81941,16141,160-0.8%
Long-term debt including finance leases23,98524,60724,153-0.7%
Finance lease liabilities50.050.056.0-10.7%
Shareholders' equity49,38748,49451,792-4.6%

Quarterly results, the last 12 quarters

Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026 *Q1 FY2027
Revenue7,9848,0898,5897,9158,4038,2928,9278,5788,9619,0179,8089,756
Cost of revenue2,7612,7823,0452,7612,9462,7793,1463,0013,0613,2613,3983,416
Gross profit5,2235,3075,5445,1545,4575,5135,7815,5775,9005,7566,4106,340
Gross margin65%66%65%65%65%66%65%65%66%64%65%65%
R&D698695674676697675684726754722671771
SG&A2,6862,6732,7642,6552,7572,7172,7202,8062,9652,9563,0573,198
Operating income1,3401,4831,0531,2781,5951,6461,4361,4451,6861,4641,8721,764
Operating margin17%18%12%16%19%20%16%17%19%16%19%18%
Interest expense180188203167209179174176181181177186
Pre-tax income1,3131,4728561,2681,5591,5401,2611,3021,5971,4041,8331,769
Tax rate31%9%23%17%18%15%16%20%13%18%31%16%
Net income9091,3226541,0421,2701,2941,0561,0401,3741,1431,2441,470
Net margin11%16%8%13%15%16%12%12%15%13%13%15%
Diluted EPS$0.68$0.99$0.50$0.80$0.99$1.01$0.81$0.81$1.07$0.89$0.96$1.14
Operating cash flow6612,4742,7779869582,5722,5281,0889252,7442,5731,793
Capital expenditure461346426520404476459504468444488503
Free cash flow2002,1282,3514665542,0962,0695844572,3002,0851,290
Buybacks2261321,6282,492288181274123372105435267
Dividends paid918917913898897897897910910911908921
Shares outstanding1,330m1,330m1,311m1,282m1,283m1,283m1,282m1,282m1,282m1,283m1,280m1,280m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 24 January 2025, filed 25 February 2025, accession 0001613103-25-000022: the filing on EDGAR. All of Medtronic plc's filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install